Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

Blood

Volumn 125, Issue 6, 2015, Pages 901-906

  Valent, Peter ^a   Hadzijusufovic, Emir ^a,b   Schernthaner, Gerit Holger ^a   Wolf, Dominik ^c   Rea, Delphine ^d   Le Coutre, Philipp ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d Service D'Hé Matologie Adulte   (France)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; BCR ABL PROTEIN; PROTEIN KINASE INHIBITOR;

ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CHRONIC MYELOID LEUKEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LONG TERM CARE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLEURA EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOEMBOLISM; VASCULAR DISEASE; VASOSPASM; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; VASCULAR DISEASES;

EID: 84922342262     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-594432     Document Type: Article

References (69)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999; 341(3): 164-172.
2. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007; 7(6): 441-453.
3. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 2002; 1(1): 31-36.
4. Druker BJ, Guilhot F, O'Brien SG, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23): 2408-2417.
5. Valent P. Standard treatment of Ph1 CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor? Eur J Clin Invest. 2010; 40(10): 918-931.
6. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007; 110(7): 2242-2249.
7. Quintá s-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Contr. 2009; 16(2): 122-131.
8. Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica. 2005; 90(4): 534-541.
9. La Rosé e P, Deininger MW. Resistance to imatinib: mutations and beyond. Semin Hematol. 2010; 47(4): 335-343.
10. Radich JP. Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia. J Natl Compr Canc Netw. 2013; 11(5 suppl): 663-666.
11. Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013; 13(5): 515-529.
12. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354(24): 2542-2551.
13. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med. 2006; 354(24): 2531-2541.
14. Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011; 118(17): 4567-4576.
15. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/ or nilotinib therapy failure. Blood. 2012; 119(15): 3403-3412.
16. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012; 367(22): 2075-2088.
17. Saglio G, Kim DW, Issaragrisil S, et al; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24): 2251-2259.
18. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362(24): 2260-2270.
19. Giles FJ, Rosti G, Beris P, et al. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Rev Hematol. 2010; 3(6): 665-673.
20. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012; 30(28): 3486-3492.
21. Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007; 110(12): 4055-4063.
22. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007; 25(9): 1035-1044.
23. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008; 49(4): 615-619.
24. Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009; 23(3): 477-485.
25. Manley PW, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010; 1804(3): 445-453.
26. Quintá s-Cardama A, Kantarjian H, O'brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007; 25(25): 3908-3914.
27. Sillaber C, Herrmann H, Bennett K, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest. 2009; 39(12): 1098-1109.
28. Krauth MT, Herndlhofer S, Schmook MT, Mitterbauer-Hohendanner G, Schlö gl E, Valent P.Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2011; 96(1): 163-166.
29. Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011; 86(7): 533-539.
30. Le Coutre P, Rea D, Abruzzese E, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011; 103(17): 1347-1348.
31. Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013; 27(6): 1316-1321.
32. Cortes JE, Kim DW, Pinilla-Ibarz J, et al; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013; 369(19): 1783-1796.
33. Roux C, Nicolini FE, Rea D, et al. Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase. Blood. 2013; 122(17): 3082-3084.
34. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008; 26(19): 3204-3212.
35. Wong SF. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia. J Oncol Pharm Pract. 2009; 15(1): 17-27.
36. Eskazan AE, Soysal T, Ongoren S, Gulturk E, Ferhanoglu B, Aydin Y. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica. 2011; 96(3): e15, author reply e16-e17.
37. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res. 2009; 33(6): 861-864.
38. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012; 125(17): 2128-2137.
39. Sano M, Saotome M, Urushida T, et al. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-. Intern Med. 2012; 51(17): 2337-2340.
40. Hochhaus A, Cortes JE, Kim DW, et al. Efficacy and safety of ponatinib following failure of dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) in the PACE trial. Blood. 2013; 122(12). Abstract 1498.
41. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008; 111(4): 1834-1839.
42. Breccia M, Loglisci G, Cannella L, et al. Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences. Leuk Res. 2011; 35(11): e215-e216.
43. Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholesterolemia induced by the 2ndgeneration tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014; 99(7): 1197-1203.
44. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or nontyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013; 27(6): 1310-1315.
45. Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol. 2013; 90(6): 531-532.
46. Mirault T, Rea D, Azarine A, Messas E. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome [published online ahead of print May 3, 2014]. Eur J Haematol.
47. Quintá s-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012; 12(5): 337-340.
48. Mayer K, Gielen GH, Willinek W, Müller MC, Wolf D. Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib. Leukemia. 2014; 28(4): 976-977.
49. Kantarjian HM, Cortes JE, Kim DW, et al. Efficacy and safety of ponatinib following failure of nilotinib in patients with chronic phase chronic myeloid leukemia (CP-CML) in the PACE trial. Blood. 2013; 122(12). Abstract 2738.
50. Cortes JE, Kantarjian HM, Khoury HJ, et al. Longterm evaluation of vascular toxicity in patients with Ph1 leukemias treated with bosutinib. J Clin Oncol. 2014; 32: 5s. ASCO abstract 7060.
51. Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014; 89(10): 947-953.
52. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012; 26(10): 2197-2203.
53. Hadzijusufovic E, Albrecht-Schgoer K, Huber K, et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-iduced vasculopathy in CML. Blood. 2013; 122(12). Abstract 257.
54. Rea D, Mirault T, Raffoux E, et al. Identification of patients (pts) with chronic myeloid leukemia (CML) at high risk of artery occlusive events (AOE) during treatment with the 2nd generation tyrosine kinase inhibitor (TKI) nilotinib using risk stratification for cardiovascular diseases (CVD). Blood. 2013; 122(12). Abstract 2726.
55. Labussiere-Wallet H, Guillermin Y, Etienne M, et al. Analysis of clinical arterial and metabolic parameters in chronic phase cml patients on nilotinib in a single center cohort. Blood. 2012; 120(21). Abstract 3756.
56. Saglio G, Hochhaus A, Hughes TP, et al. ENESTnd Update: nilotinib (NIL) vs imatinib (IM) in patients (PTS) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and sokal risk at diagnosis on long-term outcomes. Blood. 2013; 122(21). Abstract 92.
57. Hiwase DK, Yeung DT, Carne L, et al. Hypercholesterolemia in imatinib intolerant/resistant CML-CP patients treated with nilotinib: a retrospective analysis. Blood. 2013; 122(21). Abstract 1503.
58. Gora-Tybor J, Medras E, Calbecka M, et al. Real-life comparison of severe vascular events and other non-hematological complications in CML patients treated with second line nilotinib or dasatinib. Blood. 2013; 122(21). Abstract 1491.
59. Jeon YW, Lee SE, Choi SY, et al. Peripheral arterial occlusive disease (PAOD) in chronicphase chronic myeloid leukemia patients treated with nilotinib. Blood. 2013; 122(21). Abstract 4018.
60. Hehlmann R, Lauseker M, Schreiber A, et al. Adverse events (AE) under imatinib treatment over 10 years: results from 1501 patients of the randomized CML-study IV. Blood. 2013; 122(12). Abstract 4012.
61. Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph1 chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol. 2004; 22(22): 4653-4655.
62. Lassila M, Allen TJ, Cao Z, et al. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24(5): 935-942.
63. Breccia M, Latagliata R, Stagno F, et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica. 2011; 96(10): 1457-1461.
64. de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008; 141(5): 745-747.
65. Valent P. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Haematologica. 2011; 96(10): 1395-1397.
66. Aprile L, Puccetti L, Galimberti S, et al. Atherothrombotic risk and TKI treatment In chronic myeloid leukemia patients: a role for genetic predisposition and pro-inflammatory/pro-oxidative status? Blood. 2013; 122(12). Abstract 1482.
67. Racil Z, Razga F, Drapalova J, et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica. 2013; 98(10): e124-e126.
68. Breccia M, Muscaritoli M, Gentilini F, et al. Impaired fasting glucose level as metabolicside effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res. 2007; 31(12): 1770-1772.
69. Mahon FX, Ré a D, Guilhot J, et al; Intergroupe Français des Leucé mies Myé loï des Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11): 1029-1035.